Scientists at Baylor College of Medicine in the United States have identified an experimental drug, CS18, that may disrupt a key survival strategy of cancer cells. In laboratory experiments, CS18 restored the sensitivity of lung cancer cells that had become resistant to osimertinib, a drug used to treat certain lung cancers. When the two drugs were combined, more cancer cells died. The researchers report that the drug has shown early potential to weaken biological defences that help cancer cells survive treatment and make some resistant tumours sensitive to existing drugs again.
Related Articles
Don't miss out on breaking stories and in-depth articles.